Theriva Biologics, Inc.TOVXNYSE
Loading
Book Value/Share Growth Recovery in ProgressRecovering
Percentile Rank18
Year-over-Year Change
Year-over-year book value per share growth
Latest
-55.74%
↓ 260% vs avg
Percentile
P18
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
34.78%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | -55.74% |
| Q2 2025 | -71.76% |
| Q1 2025 | -60.62% |
| Q4 2024 | -34.87% |
| Q3 2024 | -39.12% |
| Q2 2024 | -28.30% |
| Q1 2024 | -14.04% |
| Q4 2023 | -10.10% |
| Q3 2023 | -18.22% |
| Q2 2023 | -5.86% |
| Q1 2023 | -3.58% |
| Q4 2022 | 2262.92% |
| Q3 2022 | -5.72% |
| Q2 2022 | -20.92% |
| Q1 2022 | -0.63% |
| Q4 2021 | -7.30% |
| Q3 2021 | -4.30% |
| Q2 2021 | -34.00% |
| Q1 2021 | 240.10% |
| Q4 2020 | 22.72% |
| Q3 2020 | -35.89% |
| Q2 2020 | -37.20% |
| Q1 2020 | -26.31% |
| Q4 2019 | -21.20% |
| Q3 2019 | -27.12% |
| Q2 2019 | -19.05% |
| Q1 2019 | -14.00% |
| Q4 2018 | 5.04% |
| Q3 2018 | 59.95% |
| Q2 2018 | -46.65% |
| Q1 2018 | 305.44% |
| Q4 2017 | 48.96% |
| Q3 2017 | -315.73% |
| Q2 2017 | 271.64% |
| Q1 2017 | -70.07% |
| Q4 2016 | 133.13% |
| Q3 2016 | -738.90% |
| Q2 2016 | -81.33% |
| Q1 2016 | -66.79% |
| Q4 2015 | -43.56% |